Product Name: MabThera/Rituxan [rituximab]
Date of Report: 12/22/2003
Phase: III
An Open-Label, Randomized, Multi-Center Study Comparing Standard Cyclophosphamide, Vincristine, Prednisolone (CVP) Chemotherapy with Rituximab plus CVP (R-CVP) in Patients with Previously Untreated CD20-Positive Follicular Lymphoma (Stage III-IV)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 6/1/2004
Phase: II
A randomized, double dummy controlled, parallel group study of the efficacy and safety of MabThera (rituximab) alone or in combination with either cyclophosphamide or methotrexate, in patients with rheumatoid arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 12/1/2004
Phase: IV
Treatment of Mantle Cell Non Hodgkin’s Lymphoma with Rituximab after Autologous Marrow or Peripheral Blood Stem Cell Transplantation
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 2/8/2005
Phase: III
An open-labeled, randomized, multicenter Phase III clinical trial of first-line treatment for patients with CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma with a standard CHOP chemotherapy regimen with or without rituximab (MabThera) (IDEC-C2B8).
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 2/24/2005
Phase: II
Treatment of follicular and mantle cell non-Hodgkin’s lymphoma with anti-CD20 antibody rituximab (IDEC-C2B8) after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem-cell transplantation.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 4/1/2005
Phase: III
A randomized intergroup trial of first-line treatment for patients with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like chemotherapy regimen with or without the anti-CD20 antibody rituximab.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study to Evaluate MabThera (Rituximab) in Patients Previously Treated for Chronic Lymphocytic Leukemia
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination with a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 7/1/2005
Phase: II
A randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (MabThera/Rituxan) in combination with methotrexate in patients with active rheumatoid arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study to Assess the Safety and Efficacy of Retreatment with MabThera (rituximab) in Patients with Rheumatoid Arthritis Who Have Failed on anti-TNFα Therapy
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study to Assess the Efficacy and Safety of Retreatment with MabThera (rituximab) in Patients with Active Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 7/27/2005
Phase: III
A randomized, placebo-controlled, double-blind, mulitcenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to anti-TNF therapies.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin’s Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Mabthera (Rituximab) in Patients With Advanced Non-Hodgkin’s Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Patients with HIV-Related Non-Hodgkin’s Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) as Maintenance Therapy in Patients With Aggressive Non-Hodgkin’s Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia (CLL)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) Alone and in Combination with Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin’s Lymphoma (NHL)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of Induction and Maintenance Treatment with MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Combination Chemotherapy in Patients with B-Cell Chronic Lymphocytic Leukemia
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Patients With Advanced Follicular Lymphoma
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
CHAIROS study A Study of MabThera (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination With Methotrexate in Methotrexate-Naive Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Pharmacokinetic and Pharmacodynamic Study of MabThera (rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatiod Arthritis Who Have Failed on Anti-TNF alpha therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior anti-TNF Therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Quality of Life Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 2/1/2007
Phase: II
A phase II, multicenter, open-label trial on the efficacy and safety of Rituximab therapy in patients with B-cell post-transplant lymphoproliferative disorders (B-PTLD) (organ or bone marrow transplant recipients) with progressive disease after immunosuppressive therapy reduction or discontinuation.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to anti-TNF Therapies.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 5/2/2007
Phase: II
An open, uncontrolled, monocentric clinical trial to evaluate activity and toxicity of rituximab in chronic lymphocytic leukemia (CLL) patients responsive to first line therapy with chlorambucil (CB) and prednisone (PDN).
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to anti-TNF Agents.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD and/or anti-TNF Therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 8/7/2007
Phase: II
In vivo purging with High Dose Sequential chemotherapy and Rituximab monoclonal antibody (R-HDS), in newly diagnosed mantle cell lymphoma.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had An Inadequate Response to a Single anti-TNF Inhibitor.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
R.A. SCORE Study: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Maintenance Treatment With MabThera (Rituximab) in Patients With Progressive B-cell Chronic Lymphocytic Leukemia.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study of MabThera (Rituximab) plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia.
